Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice.
Taro HiraiMunehiro KitadaItaru MonnoErina OdaYoshihiro HayashiKeiji ShimadaYuta TakagakiYoshio OguraMizue FujiiKazunori KonishiMasaru SakuraiAtsushi NakagawaDaisuke KoyaPublished in: Journal of diabetes investigation (2021)
SGLT2is administration slows the decline observed in the annual renal function in type 2 diabetes mellitus patients with eGFR of <60 mL/min/1.73 m2 in clinical practice.